Overview

Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI

Status:
Not yet recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The aim of this study is to assess the efficacy and safety of rivaroxaban or aspirin combined with clopidogrel in patients with coronary heart disease and gastrointestinal diseases undergoing PCI.
Phase:
Phase 4
Details
Lead Sponsor:
Shenyang Northern Hospital
Treatments:
Clopidogrel
Rivaroxaban